RAS/MAPK Activation is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Sherene Loi,Sathana Dushyanthen,Paul A Beavis,Roberto Salgado,Carsten Denkert,Peter Savas,Susan Combs,David L Rimm,Jennifer M Giltnane,Monica V Estrada,Violeta Sánchez,Melinda E Sanders,Rebecca S Cook,Mark A Pilkinton,Simon A Mallal,Kai Wang,Vincent A Miller,Phil J Stephens,Roman Yelensky,Franco D Doimi,Henry Gómez,Sergey V Ryzhov,Phillip K Darcy,Carlos L Arteaga,Justin M Balko
DOI: https://doi.org/10.1158/1078-0432.ccr-15-1125
2015-01-01
Abstract:PURPOSE:Tumor-infiltrating lymphocytes (TIL) in the residual disease (RD) of triple-negative breast cancers (TNBC) after neoadjuvant chemotherapy (NAC) are associated with improved survival, but insight into tumor cell-autonomous molecular pathways affecting these features are lacking.EXPERIMENTAL DESIGN:We analyzed TILs in the RD of clinically and molecularly characterized TNBCs after NAC and explored therapeutic strategies targeting combinations of MEK inhibitors with PD-1/PD-L1-targeted immunotherapy in mouse models of breast cancer.RESULTS:Presence of TILs in the RD was significantly associated with improved prognosis. Genetic or transcriptomic alterations in Ras-MAPK signaling were significantly correlated with lower TILs. MEK inhibition upregulated cell surface MHC expression and PD-L1 in TNBC cells both in vivo and in vitro. Moreover, combined MEK and PD-L1/PD-1 inhibition enhanced antitumor immune responses in mouse models of breast cancer.CONCLUSIONS:These data suggest the possibility that Ras-MAPK pathway activation promotes immune-evasion in TNBC, and support clinical trials combining MEK- and PD-L1-targeted therapies. Furthermore, Ras/MAPK activation and MHC expression may be predictive biomarkers of response to immune checkpoint inhibitors.